Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9N8WM)

• Drug Name: Ciproxifan Drug Info
• Synonyms: ciproxifan; 184025-18-1; FUB-359; FUB 359; FUB359; UNII-5EVQ7IRG99; 5EVQ7IRG99; CHEMBL14638; ACQBHJXEAYTHCY-UHFFFAOYSA-N; cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone; (4-(3-(1H-imidazol-4-yl)propoxy)phenyl)(cyclopropyl)methanone; Ciproxifan; FUB 359; Methanone, cyclopropyl(4-(3-(1H-imidazol-5-yl)propoxy)phenyl)-; Ciproxifan (FUB-359); AC1O4Y0P; GTPL1265; SCHEMBL3335184; BDBM27213; EX-A077; DTXSID50171532; cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxyphenyl)ketone; CHEBI:125467; MolPort-027-720-958; ZINC1892860

Indication

Disease Entry	ICD 11	Status	REF
Dementia	6D80-6D86	Investigative	[1]
Obesity	5B81	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6422124
  ChEBI ID: CHEBI:125467
  CAS Number: CAS 184025-18-1
  TTD Drug ID: DM9N8WM

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[3]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[4]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[5]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[6]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[7]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[8]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[9]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[10]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[11]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[12]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[13]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[3]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[14]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[15]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[16]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[17]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[18]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[19]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[20]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[21]

Drug(s) Targeting Histamine H3 receptor (H3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pitolisant	DM8RFNJ	Excessive daytime sleepiness	MG42	Approved	[22]
SUVN-G3031	DM3BO8G	Cognitive impairment	6D71	Phase 3	[23]
JNJ-17216498	DM1GRCU	Narcolepsy	7A20	Phase 2	[24]
GSK239512	DMBJMZC	Alzheimer disease	8A20	Phase 2	[25]
JNJ-39220675	DM0WY3H	Alcohol dependence	6C40.2	Phase 2	[26]
AZD-5213	DMOZ04X	Alzheimer disease	8A20	Phase 2	[27]
Bavisant	DM6CVZ5	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[28]
ABT-288	DM7X54F	Alzheimer disease	8A20	Phase 2	[29]
SAR-110894	DMCLEXM	Alzheimer disease	8A20	Phase 2	[27]
ABT-652	DMLEO2Z	Diabetic neuropathy	8C0Z	Phase 2	[30]

Drug(s) Targeting 5-HT 3 receptor (5HT3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ondansetron	DMOTQ1I	Chemotherapy-induced nausea	MD90	Approved	[31]
Granisetron	DMIUW25	Malignant glioma	2A00.0	Approved	[32]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[33]
Y-25130	DMDPM7R	Nausea and vomiting	MD90	Approved	[34]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[35]
LITOXETINE	DMKZRBP	Mood disorder	6A60-6E23	Phase 3	[36]
Zatosetron maleate	DMWDEFC	Anxiety disorder	6B00-6B0Z	Phase 3	[37]
Pancopride	DMIRYU9	Nausea	MD90	Phase 3	[38]
Lerisetron	DMOTCIU	Nausea	MD90	Phase 3	[39]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[40]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3 receptor (5HT3R)	TTNXLKE	NOUNIPROTAC	Antagonist	[2]
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Antagonist	[2]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[2]
Histamine H3 receptor (H3R)	TT9JNIC	HRH3_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1265).
• [2] The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
• [3] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [4] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [6] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [7] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [8] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [9] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [10] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [11] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [12] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [15] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [16] Clinical pipeline report, company report or official report of Klus Pharma
• [17] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [20] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [21] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [22] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
• [25] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [26] JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
• [27] SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
• [28] Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
• [29] A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
• [31] Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
• [32] New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
• [33] Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
• [34] The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
• [35] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [36] Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
• [37] Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
• [38] Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
• [39] Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
• [40] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.